论文部分内容阅读
通过注射人B淋巴细胞激活因子(hsBAFF)的全人源抗体scFv-Fc,观察其对hsBAFF引发的B细胞增殖与分化的拮抗作用。将ICR小鼠随机分为对照组、hsBAFF(1 mg.kg 1)组、hsBAFF(1 mg.kg 1)+Ab(1mg.kg 1)组、hsBAFF(1 mg.kg 1)+Ab(2 mg.kg 1)组、hsBAFF(1 mg.kg 1)+human IgG(1 mg.kg 1)组和hsBAFF(1 mg.kg 1)+human IgG(2 mg.kg 1)组。采用MTT、ELISA及流式细胞检测,分别考察各组小鼠脾脏指数、脾脏B淋巴细胞增殖活性及成熟分化和血浆中抗体水平。结果表明:通过注射scFv-Fc有效抑制了hsBAFF引起的脾脏B细胞增殖以及血浆中抗体水平的升高;同时scFv-Fc也显著抑制了hsBAFF引发的B细胞成熟分化,具有潜在的抗体药物开发价值。
The human anti-human scFv-Fc of human B lymphocyte activation factor (hsBAFF) was injected to observe its antagonism on hsBAFF-induced B cell proliferation and differentiation. The ICR mice were randomly divided into control group, hsBAFF (1 mg.kg 1), hsBAFF (1 mg.kg 1) + Ab (1 mg.kg 1), hsBAFF (1 mg.kg 1) + Ab mg.kg 1), hsBAFF (1 mg.kg 1) + human IgG (1 mg.kg 1) and hsBAFF (1 mg.kg 1) + human IgG (2 mg.kg 1). MTT, ELISA and flow cytometry were used to detect the spleen index, splenic B lymphocyte proliferation activity and maturation differentiation and plasma antibody levels in each group. The results showed that scFv-Fc could effectively inhibit the proliferation of B lymphocytes induced by hsBAFF and the level of antibody in plasma. Meanwhile, scFv-Fc also significantly inhibited the maturation and differentiation of B cells induced by hsBAFF, which has the potential value of antibody drug development .